# CJC-1295 Research: GH, IGF-1, Mechanism, and the Ipamorelin Pairing > CJC-1295 raised basal GH ~7.5-fold and mean GH ~46% one week after a single dose while preserving pulsatility (Ionescu/Frohman 2006). The mechanism, the GH/IGF-1 data, and the concerns, cited. Every major finding from the peer-reviewed CJC-1295 literature, tagged by the strength of evidence behind it. ## The mechanism: one receptor, a looping axis CJC-1295 binds the growth-hormone-releasing hormone receptor, a class B G-protein-coupled receptor on anterior-pituitary somatotrophs. Binding activates Gs, adenylate cyclase, cAMP and PKA, driving CREB-mediated growth-hormone gene transcription and pulsatile GH release [2]. The released GH reaches the hepatic GH receptor, signals through JAK2/STAT5, and raises IGF-1 — which feeds back on the axis. The mechanism is a loop, not a line. What makes CJC-1295 long-acting is not a different receptor but a different residence time. The four protease-resistant substitutions block dipeptidylpeptidase-IV cleavage, and the DAC albumin bioconjugation keeps the peptide in circulation for days, so a single dose sustains GHRH-receptor stimulation rather than producing a single brief pulse [2]. In the original discovery work, the albumin-conjugated lead produced a four-fold increase in GH area-under-the-curve over two hours versus unconjugated hGRF(1-29) in rats, with peptide detectable in plasma beyond 72 hours [2]. ## The development arc: from native GHRH to a long-acting lead CJC-1295 is the product of a deliberate engineering sequence, and reading it as an arc explains the molecule. It starts from hGRF(1-29), the active N-terminal fragment of native GHRH. Native GHRH is cleared in minutes, so the first move was four substitutions (D-Ala2, Gln8, Ala15, Leu27) that block dipeptidylpeptidase-IV cleavage and stabilize the helix [2]. The second move was the DAC albumin handle — a maleimidopropionyl linker that covalently couples the peptide to serum albumin, extending residence toward that of albumin itself [2]. That second step is where CJC-1295 was named. The discovery work screened a series of hGRF(1-29)-albumin bioconjugates and identified CJC-1295 as the lead long-lasting GHRH analog; the conjugated lead produced a four-fold increase in GH area-under-the-curve over two hours versus the unconjugated peptide in rats, with peptide detectable in plasma beyond 72 hours [2]. A 2025 Nature Reviews Endocrinology review places this long-acting-analog design strategy in the broader context of the GHRH class [12]. The arc also has an analytical coda. CJC-1295 has been positively identified by high-resolution LC-MS/MS as the active ingredient in a seized "GHRH" preparation [6], and modern doping-control methods cover peptides in its 2-10 kilodalton size class [13] — the assays that make the long-acting analog traceable in practice. ## What the GH/IGF-1 research reports The strongest CJC-1295 data are pharmacodynamic. In healthy adults aged 21 to 61, single subcutaneous doses of 30 or 60 micrograms per kilogram raised mean plasma GH two- to ten-fold for six or more days and IGF-1 1.5- to three-fold for nine to eleven days; after multiple doses, IGF-1 stayed above baseline up to 28 days, and the estimated half-life was 5.8 to 8.1 days [1]. A separate study in healthy men aged 20 to 40 sharpened the picture. A single 60- or 90-microgram-per-kilogram dose raised basal GH roughly 7.5-fold and, one week later, mean GH by about 46% and IGF-1 by about 45% — while the frequency and amplitude of pulsatile GH secretion were unchanged [3]. That last point is the notable one: GH pulsatility persists under continuous GHRH-analog stimulation. In GHRH-knockout mice, 2 micrograms once every 24 hours fully normalized body weight and length, while less frequent dosing was progressively inferior — evidence that the long-acting schedule restores GH-axis-dependent growth [4]. The axis activation is even traceable in the blood proteome: in 11 healthy young men, CJC-1295 shifted several serum proteins, and one immunoglobulin/albumin-fragment signal correlated linearly with IGF-1, flagging candidate biomarkers of GH/IGF-1 activation [5]. ## CJC-1295 and ipamorelin: the two-receptor rationale GHRH analogs and growth-hormone-releasing peptides act through distinct receptors and synergize — the mechanistic basis for pairing CJC-1295 (a GHRH analog) with ipamorelin (a selective GHRP/secretagogue). Ipamorelin acts on the ghrelin/GHS receptor; its pharmacokinetic-pharmacodynamic profile and GH-releasing potency are characterized in animal modeling [10], and it has been shown to counteract glucocorticoid-induced decreases in bone formation in rodents [11]. The rationale is sound, but the evidence stops at mechanism. There is no controlled human trial of the CJC-1295/ipamorelin combination's efficacy or safety; the fixed-dose protocols that circulate online are not derived from trials [1]. Distinct secretagogues exert differential control over pulsatile GH secretion in healthy men [9], which is part of why layered stimulation is studied — and part of why its net effect is not assumed from the parts. ### What is CJC-1295 ipamorelin? A frequently studied pairing of CJC-1295 (a GHRH analog) with ipamorelin (a selective GHRP/secretagogue). The two engage different receptors — the GHRH receptor and the ghrelin/GHS receptor — which is the basis for combining them in growth-hormone-axis research [10]. ### Does CJC-1295 and ipamorelin work? The mechanistic rationale is sound: GHRH analogs and GHRPs synergize to raise GH more than either alone, and ipamorelin is a selective GH secretagogue [10]. But there are no controlled efficacy trials of the CJC-1295/ipamorelin combination in healthy adults, so "works" is undefined past the endocrine readouts [1]. ## Reported and theoretical concerns in the literature CJC-1295 raises GH and IGF-1, and sustained elevation of that axis carries the concerns that come with it. Fluid retention, edema and effects on insulin sensitivity are recognized consequences of GH-axis stimulation. Epidemiology links higher circulating IGF-1 to a modestly increased risk of certain cancers, which is why durable IGF-1 elevation is treated as a theoretical safety question rather than a benign one. FDA briefing materials prepared for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other safety concerns for growth-hormone secretagogues including CJC-1295. The committee did not recommend CJC-1295 for the list of substances pharmacies may compound. CJC-1295 is also prohibited at all times in sport under Section S2 of the WADA Prohibited List, and is banned by bodies such as the NCAA. The honest summary: controlled long-term safety data in healthy adults do not exist. The published human evidence is limited to early pharmacokinetic studies [1][3], and the original long-acting DAC program was discontinued. A patient death during the development era is frequently cited in connection with the halted Phase 2 trial, though a causal link to CJC-1295 was not established in the public record. The [regulatory and WADA status](/faq) is covered in full on the FAQ. ### What to expect when taking CJC-1295? In the research setting, CJC-1295 produced dose-dependent, multi-day elevation of GH and IGF-1 while preserving GH pulsatility [1][3]. Outcomes beyond those pharmacokinetic and endocrine readouts are not established in controlled human trials, and nothing here is a use recommendation. --- A corporate process deck mapping the CJC-1295 record phase by phase — the GH and IGF-1 kinetics logged to source, the DAC-versus-no-DAC split kept apart, and the missing efficacy and long-term safety data marked, not filled; no clinic behind the deck and nothing here listed, priced, or sold.